01296nas a2200217   4500000000100000008004100001260004100042653000900083653004700092653001200139653001000151653001500161100001500176700001400191700001300205700001700218245015100235856006400386490000700450520062100457       2022                            d  bUniversala Medicina Esperanto Asocio10aLPRF10aLeukocyte and Platelet-Rich Fibrin Therapy10aLeprosy10aNepal10aResistance1 aHoughton F1 aStritch M1 aTamang K1 aWinterburn M00aLeukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy:: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings  uhttps://interrev.com/mir/index.php/mir/article/view/207/1580 v303 a<p>This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.</p>